Literature DB >> 29891646

mPGES-1 (Microsomal Prostaglandin E Synthase-1) Mediates Vascular Dysfunction in Hypertension Through Oxidative Stress.

María S Avendaño1, Ana B García-Redondo1,2, Guillermo Zalba3, María González-Amor1, Andrea Aguado1, Sonia Martínez-Revelles1,2, Luis M Beltrán4, Mercedes Camacho2,5, Victoria Cachofeiro2,6, María J Alonso2,7, Mercedes Salaices1,2, Ana M Briones8,2.   

Abstract

mPGES-1 (microsomal prostaglandin E synthase-1), the downstream enzyme responsible for PGE2 (prostaglandin E2) synthesis in inflammatory conditions and oxidative stress are increased in vessels from hypertensive animals. We evaluated the role of mPGES-1-derived PGE2 in the vascular dysfunction and remodeling in hypertension and the possible contribution of oxidative stress. We used human peripheral blood mononuclear cells from asymptomatic patients, arteries from untreated and Ang II (angiotensin II)-infused mPGES-1-/- and mPGES-1+/+ mice, and vascular smooth muscle cells exposed to PGE2 In human cells, we found a positive correlation between mPGES-1 mRNA and carotid intima-media thickness (r=0.637; P<0.001) and with NADPH oxidase-dependent superoxide production (r=0.417; P<0.001). In Ang II-infused mice, mPGES-1 deletion prevented all of the following: (1) the augmented wall:lumen ratio, vascular stiffness, and altered elastin structure; (2) the increased gene expression of profibrotic and proinflammatory markers; (3) the increased vasoconstrictor responses and endothelial dysfunction; (4) the increased NADPH oxidase activity and the diminished mitochondrial membrane potential; and (5) the increased reactive oxygen species generation and reduced NO bioavailability. In vascular smooth muscle cells or aortic segments, PGE2 increased NADPH oxidase expression and activity and reduced mitochondrial membrane potential, effects that were abolished by antagonists of the PGE2 receptors (EP), EP1 and EP3, and by JNK (c-Jun N-terminal kinase) and ERK1/2 (extracellular-signal-regulated kinases 1/2) inhibition. Deletion of mPGES-1 augmented vascular production of PGI2 suggesting rediversion of the accumulated PGH2 substrate. In conclusion, mPGES-1-derived PGE2 is involved in vascular remodeling, stiffness, and endothelial dysfunction in hypertension likely through an increase of oxidative stress produced by NADPH oxidase and mitochondria.
© 2018 American Heart Association, Inc.

Entities:  

Keywords:  angiotensin II; hypertension; oxidative stress; prostaglandins; vascular remodeling

Mesh:

Substances:

Year:  2018        PMID: 29891646     DOI: 10.1161/HYPERTENSIONAHA.118.10833

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  8 in total

1.  Biological characterization of new inhibitors of microsomal PGE synthase-1 in preclinical models of inflammation and vascular tone.

Authors:  Karin Larsson; Julia Steinmetz; Filip Bergqvist; Samsul Arefin; Linda Spahiu; Johan Wannberg; Sven-Christian Pawelzik; Ralf Morgenstern; Patric Stenberg; Karolina Kublickiene; Marina Korotkova; Per-Johan Jakobsson
Journal:  Br J Pharmacol       Date:  2019-12-28       Impact factor: 8.739

Review 2.  Animal Models of Hypertension: A Scientific Statement From the American Heart Association.

Authors:  Lilach O Lerman; Theodore W Kurtz; Rhian M Touyz; David H Ellison; Alejandro R Chade; Steven D Crowley; David L Mattson; John J Mullins; Jeffrey Osborn; Alfonso Eirin; Jane F Reckelhoff; Costantino Iadecola; Thomas M Coffman
Journal:  Hypertension       Date:  2019-06       Impact factor: 10.190

3.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

4.  Central Blockade of E-Prostanoid 3 Receptor Ameliorated Hypertension Partially by Attenuating Oxidative Stress and Inflammation in the Hypothalamic Paraventricular Nucleus of Spontaneously Hypertensive Rats.

Authors:  Fang-Fang Wang; Xiao-Jing Yu; Qiu-Yue Yi; Juan Ba; Xiao-Lian Shi; Jin-Jun Liu; Kai-Li Liu; Li-Yan Fu; Qing Su; Hong-Bao Li; Kai B Kang; Shu-Qiu Wang; Hong-Li Gao; Jie Qi; Ying Li; Guo-Qing Zhu; Yu-Ming Kang
Journal:  Cardiovasc Toxicol       Date:  2020-11-09       Impact factor: 3.231

5.  Pharmacological Characterization of the Microsomal Prostaglandin E2 Synthase-1 Inhibitor AF3485 In Vitro and In Vivo.

Authors:  Luigia Di Francesco; Annalisa Bruno; Emanuela Ricciotti; Stefania Tacconelli; Melania Dovizio; Paloma Guillem-Llobat; Maria Alessandra Alisi; Beatrice Garrone; Isabella Coletta; Giorgina Mangano; Claudio Milanese; Garret A FitzGerald; Paola Patrignani
Journal:  Front Pharmacol       Date:  2020-04-02       Impact factor: 5.810

6.  Enhanced mPGES-1 Contributes to PD-Related Peritoneal Fibrosis via Activation of the NLRP3 Inflammasome.

Authors:  Qimei Luo; Qinghua Hu; Qingkun Zheng; Lewei Gong; Lijuan Su; Baojun Ren; Yongle Ju; Zhanjun Jia; Xianrui Dou
Journal:  Front Med (Lausanne)       Date:  2021-05-18

7.  Temporal relationship between systemic endothelial dysfunction and alterations in erythrocyte function in a murine model of chronic heart failure.

Authors:  Tasnim Mohaissen; Bartosz Proniewski; Marta Targosz-Korecka; Anna Bar; Agnieszka Kij; Katarzyna Bulat; Aleksandra Wajda; Aneta Blat; Karolina Matyjaszczyk-Gwarda; Marek Grosicki; Anna Tworzydlo; Magdalena Sternak; Kamila Wojnar-Lason; Raquel Rodrigues-Diez; Agata Kubisiak; Ana Briones; Katarzyna M Marzec; Stefan Chlopicki
Journal:  Cardiovasc Res       Date:  2022-09-20       Impact factor: 13.081

Review 8.  New progress on the study of aortic stiffness in age-related hypertension.

Authors:  John O Onuh; Hongyu Qiu
Journal:  J Hypertens       Date:  2020-10       Impact factor: 4.776

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.